Ravi Manjithaya

Dr. Ravi Manjithaya


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2017 in Oncogene
Verified
Journal Article
Closed access
PDF file
SSShikha Satendra Singh
Shikha Satendra Singh
SVSomya Vats
Somya Vats
ACAmelia Yi-Qian Chia
Amelia Yi-Qian Chia
TTTuan Zea Tan
Tuan Zea Tan
SDShuo Deng
Shuo Deng
Alan Prem KumarAlan Prem Kumar
Alan Prem Kumar

15 February 2010 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RMRavi Manjithaya
Ravi Manjithaya
CAChristophe Anjard
Christophe Anjard
WLWilliam F. Loomis
William F. Loomis
SSSuresh Subramani
Suresh Subramani
In contrast to the enormous advances made regarding mechanisms of conventional protein secretion, mechanistic insights into the unconventional secretion of proteins are lacking. Acyl coenzyme A (CoA)–binding protein (ACBP; AcbA in Dictyostelium discoideum), an unconventionally secreted protein, is dependent on Golgi reassembly and stacking protein (GRASP) for its secretion. We discovered, surprisingly, that the secretion, processing, and function of an AcbA-derived peptide, SDF-2, are conserved between the yeast Pichia pastoris and D. discoideum. We show that in yeast, the secretion of SDF-2–like activity is GRASP dependent, triggered by nitrogen starvation, and requires autophagy proteins as well as medium-chain fatty acyl CoA generated by peroxisomes. Additionally, a phospholipase D implicated in soluble N-ethyl-maleimide sensitive fusion protein attachment protein receptor–mediated vesicle fusion at the plasma membrane is necessary, but neither peroxisome turnover nor fusion between autophagosomes and the vacuole is essential. Moreover, yeast Acb1 and several proteins required for its secretion are necessary for sporulation in P. pastoris. Our findings implicate currently unknown, evolutionarily conserved pathways in unconventional secretion.

1 March 2008 in Developmental Cell
Verified
Journal Article
Closed access
JFJean-Claude Farré
Jean-Claude Farré
RMRavi Manjithaya
Ravi Manjithaya
RMRichard D. Mathewson
Richard D. Mathewson
SSSuresh Subramani
Suresh Subramani

20 November 2019 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
ACAnushka Chakravorty
Anushka Chakravorty
CJCuckoo Teresa Jetto
Cuckoo Teresa Jetto
RMRavi Manjithaya
Ravi Manjithaya
Neurons are highly specialized post-mitotic cells that are inherently dependent on mitochondria owing to their high bioenergetic demand. Mitochondrial dysfunction is therefore associated with various age-related neurodegenerative disorders such as Alzheimer’s disease (AD), wherein accumulation of damaged and dysfunctional mitochondria has been reported as an early symptom further contributing to disease progression. In AD, impairment of mitochondrial function causes bioenergetic deficiency, intracellular calcium imbalance and oxidative stress, thereby aggravating the effect of Aβ and tau pathologies, leading to synaptic dysfunction, cognitive impairment and memory loss. Although there are reports suggesting intricate parallelism between mitochondrial dysfunction and AD pathologies such as Aβ aggregation and hyperphosphorylated tau accumulation, the factors that drive the pathogenesis of either are unclear. In addition, emerging evidence suggest that mitochondrial quality control (QC) mechanisms such as mitophagy are impaired in AD. As an important mitochondrial QC mechanism, mitophagy plays a critical role in maintaining neuronal health and function. Studies show that various proteins involved in mitophagy, mitochondrial dynamics, and mitochondrial biogenesis are affected in AD. Compromised mitophagy may also be attributed to impairment in autophagosome–lysosome fusion and defects in lysosomal acidification. Therapeutic interventions aiming to restore mitophagy functions can be used as a strategy for ameliorating AD pathogenesis. Recent evidence implicates the role of microglial activation via mitophagy induction in reducing amyloid plaque load. This review summarizes the current developments in the field of mitophagy and mitochondrial dysfunction in AD.

17 January 2010 in FEBS Letters
Verified
Journal Article
Closed access
RMRavi Manjithaya
Ravi Manjithaya
TNTaras Y. Nazarko
Taras Y. Nazarko
JFJean-Claude Farré
Jean-Claude Farré
SSSuresh Subramani
Suresh Subramani

30 January 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KRK. Rajasekhar
K. Rajasekhar
SSS. N. Suresh
S. N. Suresh
RMRavi Manjithaya
Ravi Manjithaya
TGT. Govindaraju
T. Govindaraju
Alzheimer's disease is one of the devastating illnesses mankind is facing in the 21st century. The main pathogenic event in Alzheimer's disease is believed to be the aggregation of the β-amyloid (Aβ) peptides into toxic aggregates. Molecules that interfere with this process may act as therapeutic agents for the treatment of the disease. Use of recognition unit based peptidomimetics as inhibitors are a promising approach, as they exhibit greater protease stability compared to natural peptides. Here, we present peptidomimetic inhibitors of Aβ aggregation designed based on the KLVFF (P1) sequence that is known to bind Aβ aggregates. We improved inhibition efficiency of P1 by introducing multiple hydrogen bond donor-acceptor moieties (thymine/barbiturate) at the N-terminal (P2 and P3) and blood serum stability by modifying the backbone by incorporating sarcosine (N-methylglycine) units at alternate positions (P4 and P5). The peptidomimetics showed moderate to good activity in both inhibition and dissolution of Aβ aggregates as depicted by thioflavin assay, circular dichroism (CD) measurements and microscopy (TEM). The activity of P4 and P5 were studied in a yeast cell model showing Aβ toxicity. P4 and P5 could rescue yeast cells from Aβ toxicity and Aβ aggregates were cleared by the process of autophagy.